Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth predicts quick response to Tygacil "approvable" letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Wyeth anticipates submitting a complete response to FDA's "approvable" letter for a new community-acquired pneumonia indication for its I.V. antibiotic Tygacil (tigecycline) by June 27, the company says after announcing receipt of the letter on May 29. On that timetable, the sNDA would have a user fee goal of Dec. 22. FDA requested additional analyses of the antibiotic "in patients with CAP with illness severe enough to require hospitalization, including those who are at higher risk of mortality," Wyeth says. FDA also asked for benefit/risk information on the potential for liver toxicity; Wyeth maintains that such information was presented to FDA during the review period, noting that "the agency acknowledged in its letter that it had not yet reviewed that information.

You may also be interested in...

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts